Pomalyst® is the newest oral immunomodulatory drug (IMiD®). Approved by the FDA in 2013, Pomalyst is chemically related to thalidomide and lenalidomide, which was approved by the FDA in 2006, but Pomalyst has been enhanced to be more effective.
This booklet is about a drug that is used only for patients with relapsed and refractory myeloma. It presents information on Pomalyst® and how it works, the results of clinical trials and ongoing research with Pomalyst, how and when to take Pomalyst, and its possible side effects and how to manage them.
Like lenalidomide, pomalidomide is an immunomodulatory derivative (IMiD) of thalidomide. Approved by the FDA in 2013, alone and in combination with other drugs, it is showing clinical activity and is well-tolerated in patients who have relapsed after multiple prior therapies and are refractory to both lenalidomide and bortezomib.